Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-232 in Postoperative Cataract Surgery Patients
NCT07305987Phase 3Recruiting
- Sponsor
- Laboratorios Sophia
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of navtemadlin in post-operative ocular inflammation, sponsored by Laboratorios Sophia. Started Oct 2025; status: recruiting.
02
Drugs
navtemadlin
03
Conditions
post-operative ocular inflammation
Beyond the preview
Go deeper on NCT07305987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305987.